A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.
Phase of Trial: Phase III
Latest Information Update: 01 May 2015
At a glance
- Drugs Axitinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Pfizer
- 02 Jun 2012 Company added in the association field as reported by EudraCT.
- 08 Dec 2011 Status changed from completed to discontinued according to Pfizer and ClinicalTrials.gov description.
- 08 Feb 2011 Results published in the Lancet Oncology
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History